Monalizumab (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Monalizumab" in English language version.

refsWebsite

Global rank English rank

2clinicaltrials.gov

5,225^th place

4,062^nd place

4^th place

4^th place

1clinicalleader.com

low place

low place

1genengnews.com

low place

6,625^th place

1web.archive.org

1^st place

1^st place

1innate-pharma.com

low place

low place

2^nd place

2^nd place

clinicalleader.com

First Clinical Data For Monalizumab As A Single Agent In Cancer Patients Show Favorable Safety Profile

clinicaltrials.gov

doi.org

van Hall T, André P, Horowitz A, Ruan DF, Borst L, Zerbib R, Narni-Mancinelli E, van der Burg SH, Vivier E (October 2019). "Monalizumab: inhibiting the novel immune checkpoint NKG2A". Journal for Immunotherapy of Cancer. 7 (1): 263. doi:10.1186/s40425-019-0761-3. PMC 6798508. PMID 31623687.

genengnews.com

AstraZeneca Inks $1.8B in Immuno-Oncology Deals as Q1 Profit Dips

innate-pharma.com

"monalizumab". Archived from the original on 2016-12-20. Retrieved 2016-12-09.

nih.gov

ncbi.nlm.nih.gov

van Hall T, André P, Horowitz A, Ruan DF, Borst L, Zerbib R, Narni-Mancinelli E, van der Burg SH, Vivier E (October 2019). "Monalizumab: inhibiting the novel immune checkpoint NKG2A". Journal for Immunotherapy of Cancer. 7 (1): 263. doi:10.1186/s40425-019-0761-3. PMC 6798508. PMID 31623687.

pubmed.ncbi.nlm.nih.gov

van Hall T, André P, Horowitz A, Ruan DF, Borst L, Zerbib R, Narni-Mancinelli E, van der Burg SH, Vivier E (October 2019). "Monalizumab: inhibiting the novel immune checkpoint NKG2A". Journal for Immunotherapy of Cancer. 7 (1): 263. doi:10.1186/s40425-019-0761-3. PMC 6798508. PMID 31623687.

web.archive.org

"monalizumab". Archived from the original on 2016-12-20. Retrieved 2016-12-09.